V1RD10 Inhibitors
V1RD10 inhibitors represent a class of chemical compounds that are designed to interact selectively with a particular biological target, typically a protein or enzyme identified by the code V1RD10. The specificity of these inhibitors arises from their molecular structure, which is crafted to fit into the active site or another functional region of the V1RD10 protein. This interaction can lead to an alteration in the protein's natural function, usually resulting in the inhibition of its activity. The design of V1RD10 inhibitors is often based on the detailed understanding of the protein's three-dimensional structure, which can be elucidated through techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. The inhibitors are typically small molecules, optimized through a process of medicinal chemistry to maximize their binding affinity and selectivity for the target V1RD10 protein.
The development of V1RD10 inhibitors is a multi-step process that involves iterative cycles of design, synthesis, and testing to refine the chemical properties of the compounds. This process often begins with the identification of a lead compound that exhibits a desired level of initial activity against the target protein. Subsequent chemical modifications to the lead compound aim to improve its potency, stability, metabolic profile, and other pharmacokinetic factors, while minimizing any off-target effects on other proteins. High-throughput screening methods may be employed to rapidly assess the activity of large libraries of compounds against the V1RD10 protein. Further refinement often includes the use of computational models to predict how changes to the chemical structure might impact the interaction with the protein. The end goal of this meticulous chemical optimization is to produce compounds with high specificity and desired functional impact on the V1RD10 protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. V1RD10's activity may be indirectly inhibited by palbociclib through the cell cycle arrest in the G1 phase, leading to downregulation of downstream targets. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cell growth and proliferation. Inhibition of mTOR can reduce the activity of V1RD10 by decreasing the overall cellular growth signals that V1RD10 may be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K. By inhibiting PI3K, the subsequent AKT signaling is downregulated, which could reduce the phosphorylation and activity of V1RD10 if it is a downstream effector of this pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that impedes the MAPK/ERK pathway. If V1RD10 functions downstream of this pathway, its activity would be indirectly reduced by the lack of ERK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor, similar to trametinib, which would decrease the activity of V1RD10 if it is regulated by the MAPK/ERK pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting proteasome activity, it can lead to the accumulation of misfolded proteins, potentially including V1RD10, and reduce its functional activity through increased degradation stress. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that could indirectly inhibit V1RD10 if it is a substrate or associated with tyrosine kinase signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is another tyrosine kinase inhibitor that specifically inhibits BCR-ABL, c-KIT, and PDGFR. If V1RD10 activity is associated with these kinases, imatinib could reduce its function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine inhibits autophagy by preventing lysosome acidification. If V1RD10 requires autophagic turnover for its activity, chloroquine would lead to its functional inhibition by preventing this process. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a reversible proteasome inhibitor. Similar to bortezomib, it could reduce V1RD10 activity by preventing its proper turnover or inducing misfolded protein stress. | ||||||